JP2022533092A5 - - Google Patents
Info
- Publication number
- JP2022533092A5 JP2022533092A5 JP2021567935A JP2021567935A JP2022533092A5 JP 2022533092 A5 JP2022533092 A5 JP 2022533092A5 JP 2021567935 A JP2021567935 A JP 2021567935A JP 2021567935 A JP2021567935 A JP 2021567935A JP 2022533092 A5 JP2022533092 A5 JP 2022533092A5
- Authority
- JP
- Japan
- Prior art keywords
- caar
- cells
- domain
- acid sequence
- achr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847121P | 2019-05-13 | 2019-05-13 | |
| US62/847,121 | 2019-05-13 | ||
| PCT/US2020/032486 WO2020231999A1 (en) | 2019-05-13 | 2020-05-12 | Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533092A JP2022533092A (ja) | 2022-07-21 |
| JP2022533092A5 true JP2022533092A5 (enExample) | 2023-05-19 |
| JP7649755B2 JP7649755B2 (ja) | 2025-03-21 |
Family
ID=73289319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021567935A Active JP7649755B2 (ja) | 2019-05-13 | 2020-05-12 | アセチルコリン受容体キメラ自己抗体受容体細胞の組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20220242931A1 (enExample) |
| EP (1) | EP3969587A4 (enExample) |
| JP (1) | JP7649755B2 (enExample) |
| KR (1) | KR20220007675A (enExample) |
| CN (2) | CN121204097A (enExample) |
| AU (1) | AU2020275776A1 (enExample) |
| CA (1) | CA3139131A1 (enExample) |
| IL (1) | IL287724A (enExample) |
| MX (1) | MX2021013949A (enExample) |
| WO (1) | WO2020231999A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240041927A1 (en) * | 2020-12-22 | 2024-02-08 | Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) | Chimeric autoantibody receptor (caar) comprising a nicotinic acetylcholine receptor autoantigen |
| EP4310188A1 (en) * | 2021-03-17 | 2024-01-24 | Daiichi Sankyo Company, Limited | Gene coding for chimeric receptor for anti-acetylcholine receptor autoantibody |
| IL314801A (en) * | 2022-02-22 | 2024-10-01 | Juno Therapeutics Inc | Proteinase 3 (PR3) Chimeric Autoantigen Receptor T Cells and Related Methods and Uses |
| WO2025072450A1 (en) | 2023-09-26 | 2025-04-03 | Werewolf Therapeutics, Inc. | Enhanced adoptive cell therapy |
| WO2025249959A1 (ko) * | 2024-05-30 | 2025-12-04 | (주)메디톡스 | 융합단백질 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL132972A0 (en) * | 1999-11-16 | 2001-03-19 | Yissum Res Dev Co | Pharmaceutical compositions comprising acetylcholinesterase antisense deoxynucleotides for the treatment of muscular and neuromuscular disorders |
| WO2004009775A2 (en) * | 2002-07-19 | 2004-01-29 | Targacept, Inc. | Methods and compositions relating to chimeric nicotinic receptor subunits |
| KR100719020B1 (ko) * | 2005-09-28 | 2007-05-17 | 광주과학기술원 | 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제 |
| JP4495776B1 (ja) * | 2009-07-30 | 2010-07-07 | 日本製薬株式会社 | 融合蛋白質 |
| JP2014509841A (ja) * | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| EP3166968B1 (en) * | 2014-05-02 | 2021-09-22 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| CA3020599A1 (en) * | 2016-04-15 | 2017-10-19 | The Children's Hospital Of Philadelphia | Compositions and methods of chimeric alloantigen receptor t cells |
| KR102501179B1 (ko) * | 2016-09-08 | 2023-02-16 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 중증 근무력증의 진단 및 치료를 위한 펩티드 및 이의 용도 |
| WO2018127585A1 (en) * | 2017-01-06 | 2018-07-12 | Txcell | Monospecific regulatory t cell population with cytotoxicity for b cells |
-
2020
- 2020-05-12 CN CN202511397173.6A patent/CN121204097A/zh active Pending
- 2020-05-12 EP EP20805549.1A patent/EP3969587A4/en active Pending
- 2020-05-12 KR KR1020217040645A patent/KR20220007675A/ko not_active Ceased
- 2020-05-12 MX MX2021013949A patent/MX2021013949A/es unknown
- 2020-05-12 US US17/595,203 patent/US20220242931A1/en not_active Abandoned
- 2020-05-12 CN CN202080050072.0A patent/CN114127287A/zh active Pending
- 2020-05-12 CA CA3139131A patent/CA3139131A1/en active Pending
- 2020-05-12 JP JP2021567935A patent/JP7649755B2/ja active Active
- 2020-05-12 WO PCT/US2020/032486 patent/WO2020231999A1/en not_active Ceased
- 2020-05-12 AU AU2020275776A patent/AU2020275776A1/en active Pending
-
2021
- 2021-10-31 IL IL287724A patent/IL287724A/en unknown
-
2025
- 2025-01-24 US US19/036,458 patent/US20260001934A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526795A5 (enExample) | ||
| JP2021522790A5 (enExample) | ||
| KR100454396B1 (ko) | 단백질-티로신키나제키메라에의한세포면역성의방향전환 | |
| ES2302811T3 (es) | Procedimiento para proteger transplantes de islotes alogenicos usando moleculas mutantes soblules ctla4. | |
| JP5736368B2 (ja) | 少なくとも２つのα３ドメインを含むＨＬＡ−Ｇの多量体ポリペプチド及び医薬としてのその使用 | |
| CN115175935A (zh) | Cal-t构建体及其用途 | |
| PT1372696E (pt) | Métodos para o tratamento de doenças reumáticas utilizando uma molécula ctla4 solúvel | |
| EA020508B1 (ru) | ВЫДЕЛЕННЫЕ АНТИТЕЛА К Sp35 И ИХ ПРИМЕНЕНИЕ | |
| Steinman | The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease | |
| AU2002305716A1 (en) | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules | |
| CN102088990A (zh) | 癫痫的治疗 | |
| JP2023500338A5 (enExample) | ||
| JP2019513394A5 (enExample) | ||
| JP2008537736A (ja) | 抗原特異的ｔ細胞の操作に有用な組換えｍｈｃ分子 | |
| AU676680B2 (en) | Isolation, characterization, and use of the human beta subunit of the high affinity receptor for immunoglobulin | |
| CA2429579A1 (en) | Truncated cd200 | |
| EP3898665B1 (en) | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies | |
| CN114249832B (zh) | 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用 | |
| US20160318988A1 (en) | T cell receptor binding to alwgpdpaaa, derived from human pre-pro insulin (ppi) protein | |
| HU224137B1 (hu) | Kiméra-receptorokat kódoló DNS-molekulák, a DNS-molekulákat hordozó vektorok és a DNS-molekulákat expresszáló sejtek | |
| JP2022526194A (ja) | Ｆｌｔ３特異的キメラ抗原受容体およびその使用方法 | |
| CN119095869A (zh) | 用于预防和/或治疗炎症性病症的靶向共刺激分子的具有嵌合抗原受体的调节性t细胞 | |
| CA2571350A1 (en) | Peptides for inhibiting the interaction of protein kinase a and protein kinase a anchor proteins | |
| JP2012530106A (ja) | ＨＬＡ−Ｇα１多量体及びその薬学的使用 | |
| US20070072264A1 (en) | Recombinant chimeric acetylcholine receptors and their derivatives recognized by cd4 t cells of myasthenic patients for the treatment of myasthenia gravis |